Influence of Dialysis Modality on the Treatment of Anemia in Patients with End-Stage Kidney Disease

Author:

Hamzagic Nedim1,Andjelkovic Marija23,Pirkovic Marijana Stanojevic23,Canovic Petar3,Zaric Milan3,Petrovic Dejan34

Affiliation:

1. Center of Hemodialysis, Medical Center Tutin , Tutin , Serbia

2. Center of Laboratory Diagnostics , Clinical Center Kragujevac , Kragujevac , Serbia

3. University of Kragujevac , Faculty of Medical Sciences , Kragujevac , Serbia

4. Clinic of Urology, Nephrology and Dialysis, Clinical Center Kragujevac , Kragujevac , Serbia

Abstract

Abstract Anemia is a common complication among the patients with end-stage kidney disease. Management of anemia is influenced by several factors: iron deficiency, subtherapeutic dosage of erythropoietin, microinflammation, vitamin D deficiency, increased iPTH levels and inadequate hemodialysis. The aim of the study was to examine impact of dialysis modality on blood hemoglobin level as well as status of iron, status of vitamin D, hemodialysis adequacy and erythropoietin dose. The study included 120 patients which were divided into two groups: the group of patients treated with hemodiafiltration and the group of patients treated with standard hemo-dialysis. For statistical analysis Kolmogorov-Smirnov test, Student’s t-test and Mann-Whitney U-test were used. Blood hemoglobin level and parameters of hemodialysis adequacy (Kt/V index, spKt/V index, URR index), hematocrit ad protein catabolic rate (nPCR) were statisticaly significant lower in patients treated with regular hemodialysis compared to patients treated with regular hemodiafiltration. Serum ferritin level, C-reactive protein level and average monthly dose of intravenous iron were higher in the patients treated with regular hemodialysis compared to patients treated with hemodiafiltration. Patients treated with hemodiafiltration have lower grade of microinflammation, better iron status and better control of anemia compared to the patients treated with regular hemodialysis. Dialysis modality is an important factor that influences management of anemia in the patients with end-stage kidney disease.

Publisher

Walter de Gruyter GmbH

Subject

General Medicine

Reference40 articles.

1. 1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2(4): 279-335.

2. 2. Rossert JA, Wauters JP. Recommendation for the screening and management of patients with chronic kidney disease. Nephrol Dial Transplant 2002; 17(Suppl 1): 19-28.

3. 3. Levin A. Anaemia and left ventricular hypertrophy in chronic kidney disease populations: A review of the current state ofknowledge. Kidney Int 2002; 61(Suppl 80): 35-8.

4. 4. Stojimirović B, Petrović D, Obrenović R. Hipertrofija leve komore kod bolesnika na hemodijalizi: značaj anemije. Med Pregl 2007; LX (Supl 2): 155-9.

5. 5. Petrović D, Miloradović V, Poskurica M, Stojimirović B. Dijagnostika i lečenje ishemijske bolesti srca kod bolesnika na hemodijalizi. Vojnosanit Pregl 2009; 66(11): 897-903.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3